Equity and representation in oncology clinical evidence for FDA-approved treatments and the impact of COVID-19
-
By
-
Hao Cheng
-
Jun Li
-
Ningying Mao
-
May 1, 2026
-
Clinical Scorecard: Addressing Disparities in Demographics of Oncology Clinical Trials for FDA-Approved Therapies and the Influence of COVID-19
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | |
| Target Population | Women, racial and ethnic minorities, older adults, with emphasis on increasing representation in trials. |
| Care Setting | |
Key Highlights
Guideline-Based Recommendations
Diagnosis
Management
- D
- e
- t
- a
- i
- l
-
- a
- c
- t
- i
- o
- n
- a
- b
- l
- e
-
- s
- t
- e
- p
- s
-
- f
- o
- r
-
- i
- m
- p
- l
- e
- m
- e
- n
- t
- i
- n
- g
-
- D
- i
- v
- e
- r
- s
- i
- t
- y
-
- A
- c
- t
- i
- o
- n
-
- P
- l
- a
- n
- s
-
- (
- D
- A
- P
- )
-
- i
- n
-
- c
- r
- i
- t
- i
- c
- a
- l
-
- t
- r
- i
- a
- l
- s
- .
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Women, Black, Hispanic, and older adults with cancer
Inadequate representation in trials limits the applicability of findings to diverse patient populations.
Clinical Best Practices
References
